Comparison of the Efficacy and Safety of Two Intensification Strategies in Subjects With Type 2 Diabetes Inadequately Controlled on Basal Insulin and Metformin

Inclusion Criteria:

- Informed consent obtained before any trial-related activities. (Trial-related
activities are any procedure that would not have been performed during normal
management of the subject).

- The subject must have completed the end of treatment visit of NN1250-3643 with
Insulin degludec once daily + metformin.

- Ability and willingness to adhere to the protocol including self measurement of
plasma glucose according to the protocol

Exclusion Criteria:

- Participated in NN1250-3643 and treated with insulin glargine

- Previous treatment with glucacon like peptide (GLP-1) receptor agonists (e.g.
exenatide, liraglutide)

- Impaired liver function, defined as alanine aminotransferase (ALAT) 2.5 times the
upper limit of normal at end of treatment in NN1250-3643

- Impaired renal function defined as serum-creatinine = 125 µmol/l (= 1.4 mg/dl) for
males and = 110 µmol/L (= 1.3 mg/dl) for females or according to local label for
metformin [For France: glomerular filtration rate below 60 ml/min, calculated by the
Cockroft & Gault formula] at end of treatment in NN1250-3643.